Medicine and Dentistry
Endoscopy
100%
Cetuximab
84%
Epidermal Growth Factor Receptor
74%
Radioactive Tracer
67%
Neoplasm
61%
Molecular Imaging
61%
Oral Cancer
58%
Surgical Margin
45%
Dysplasia
42%
Barrett Esophagus
38%
Lymph Node
38%
Esophageal Adenocarcinoma
25%
Lymph Node Metastasis
25%
Ex Vivo
23%
Functional Genomics
22%
Head and Neck Cancer
19%
Phase II Trials
19%
Bevacizumab
19%
Esophageal Squamous Cell Carcinoma
19%
Contrast Medium
19%
Metastatic Carcinoma
19%
Characterization of Antibody
19%
Photoacoustic Tomography
19%
Inflammatory Bowel Disease
19%
Ustekinumab
19%
Optical Imaging
19%
Immunohistochemistry
16%
Spectrofluorometry
15%
Infliximab
14%
Adalimumab
14%
Vedolizumab
14%
Osteonectin
12%
Surgery
12%
Imaging Technique
12%
Narrow Band Imaging
12%
Mouth Squamous Cell Carcinoma
12%
White Light Endoscopy
12%
Sensitivity and Specificity
12%
Esophagus
11%
Specific Tumor
10%
Drug Distribution
9%
Clinical Trial
8%
Adverse Event
8%
Glucose Transporter 1
8%
Malignant Neoplasm
6%
Esophageal Cancer
6%
Carcinogenesis
6%
Receptor Expression
6%
False Positive Result
6%
Postoperative Care
6%
Keyphrases
Receptor Targets
19%
Epidermal Growth Factor Receptor
19%
Histopathological Examination
19%
Cetuximab
19%
Tumor
19%
Oral Cancer
19%
Molecular Endoscopy
19%
Fluorescence Molecular Imaging
19%
Metastasis
19%
Lymph Node Sampling
19%
Fluorescence Endoscopy
19%
Benign Lymph Node
19%
Targeted Contrast Agent
19%
EGFR-targeting
19%
Near-infrared Fluorescence
17%
Oral Cancer Patients
12%
Fluorescent Tracer
12%
Normal Esophagus
11%
ZW800-1
9%
Optoacoustic Signal
9%
Endoscopy System
9%
Clinical Trials
8%
Patient Prognosis
6%
Histological Analysis
6%
Surgical Margin
6%
Image-guided
6%
Surgery Patients
6%
Postoperative Therapy
6%
Surgical Treatment
6%
Lymph Node Metastasis
6%
Resection
6%
Lymph Node
6%
Node-positive
6%
Formalin-fixed
6%
Excision
6%
Microscopic Evaluation
6%
Oral Tongue Squamous Cell Carcinoma (OTSCC)
6%
Primary Tumor
6%
Fluorescence Imaging
6%
Tissue Processing
6%
Resection Margin
6%
Nodal Stage
6%
PKCι
6%
Intraoperative Adjustment
6%
Multi-diameter
5%
Fluorescence Visualization
5%
Pharmacology, Toxicology and Pharmaceutical Science
Tracer
59%
Cetuximab
58%
Epidermal Growth Factor Receptor
38%
Neoplasm
35%
Barrett Esophagus
25%
Mouth Cancer
19%
Ustekinumab
19%
Optical Imaging
19%
Inflammatory Bowel Disease
19%
Head and Neck Cancer
19%
Bevacizumab
19%
Infliximab
14%
Adalimumab
14%
Vedolizumab
14%
Adverse Event
10%
Dysplasia
9%
Esophagus Cancer
9%
Drug Distribution
9%
Malignant Neoplasm
8%
Esophagus Injury
7%
Esophageal Adenocarcinoma
7%
Clinical Trial
6%
Primary Tumor
6%
Lymph Node Metastasis
6%
Mouth Squamous Cell Carcinoma
6%
Formaldehyde
6%
